NaNotics

NaNotics is developing a new class of nanomedicine focused on the selective depletion of harmful soluble proteins implicated in cancer and other diseases. The company's injectable nanoparticle platform is designed to target and clear pathogenic soluble molecules from circulation without affecting essential membrane-bound forms, offering an innovative therapeutic approach for previously undruggable targets. The technology is modular, allowing rapid adaptation to new disease indications, and is supported by a strong patent portfolio and collaborative development with leading medical institutions.